Syros Pharmaceuticals Inc. buy melinda
Start price
07.09.17
/
50%
€155.78
Target price
26.12.17
€180.40
Performance (%)
-42.39%
End price
26.12.17
€89.75
Summary
This prediction ended on 26.12.17 with a price of €89.75. The BUY prediction by melinda for Syros Pharmaceuticals Inc. performed very badly with a performance of -42.39%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Syros Pharmaceuticals Inc. | - | - | 34.309% | -88.925% |
| iShares Core DAX® | -0.268% | 5.471% | 14.271% | 19.027% |
| iShares Nasdaq 100 | 1.854% | 7.851% | 35.426% | 58.415% |
| iShares Nikkei 225® | 0.284% | 1.729% | 9.943% | 7.045% |
| iShares S&P 500 | 1.178% | 5.269% | 27.989% | 49.400% |
Comments by melinda for this prediction
In the thread Syros Pharmaceuticals Inc diskutieren
Pharma SecteurProduits
$ 17.26
0,02 (+ 0,11%) SY-1425 Rezidivierende oder refraktäre akute myeloischer Leukämie (AML) und mit hohem Risiko myelodysplastischen Syndrom (MDS) - Krebs
Phase 2 Phase 2 wurde im September 2016. Die Daten aus der PK und PD wegen ESMO 9. September 2017 ins Leben gerufen.
(Vom Mitglied beendet)
Stopped prediction by melinda for Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€76.50
24.09.20
24.09.20
€100.00
04.11.21
04.11.21
-49.54%
05.11.21
05.11.21
Syros Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€172.70
07.09.17
07.09.17
€200.00
26.12.17
26.12.17
-42.39%
26.12.17
26.12.17
Syros Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€136.02
15.03.17
15.03.17
€144.32
16.03.17
16.03.17
6.56%
16.03.17
16.03.17